News articles about Ophthotech (NASDAQ:OPHT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ophthotech earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.8345329862519 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities analysts have recently weighed in on OPHT shares. Zacks Investment Research upgraded Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a report on Monday, November 13th. ValuEngine downgraded Ophthotech from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Finally, TheStreet upgraded Ophthotech from an “e+” rating to a “c” rating in a report on Thursday, November 30th.
Ophthotech (NASDAQ OPHT) traded up $0.08 during midday trading on Friday, reaching $2.86. The company had a trading volume of 335,721 shares, compared to its average volume of 378,974. Ophthotech has a 52 week low of $2.24 and a 52 week high of $4.81. The company has a market cap of $103.07, a P/E ratio of 1.82 and a beta of 1.43.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ophthotech (OPHT) Share Price” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/02/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ophthotech-opht-share-price.html.
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.